UNSPSC 51372034: Morphine monohydrate

This classification denotes an opiate C17H19NO3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 41TQ665R1X, chemically known as morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5-.alpha.,6-.alpha.)-, monohydrate, but more generally known as morphine monohydrate, which bears US NIH Compound Identifier 110750. Most nations, for tariff and trade purposes, schedule morphine monohydrate under HS 29391100 and SITC 54141. As of Q4 2014, MORPHINE MONOHYDRATE remains US FDA's Preferred Term for this commodity.

Morphine monohydrate bears US NLM identifiers UMLS ID C2828280 and NCI Concept Code C87362. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)O.O.

UNSPSC 51372034 Morphine monohydrate is a Commodity code that encompasses pharmaceutical products procured by state and local health and human services agencies, primarily through cooperative purchasing arrangements and competitive bidding processes. State and local governments buy under this code when sourcing controlled and non-controlled pharmaceutical inventory for health departments, community health programs, correctional facilities, and emergency response initiatives. The issuing bodies include state health and human services departments, county health agencies, and regional cooperative purchasing alliances serving multiple jurisdictions. Recent solicitations show activity spanning both direct pharmaceutical procurement and broader multi-source generic drug programs that encompass morphine and related opioid products alongside other medications and over-the-counter items.

Recent opportunities reflect three distinct procurement models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to supply through authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, designed to inform future formal solicitations. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (due July 26, 2023, though the posted date suggests a newer cycle) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, potentially FEMA-funded and subject to federal environmental compliance requirements. Geographic activity concentrates in Minnesota and Florida with cross-state reach through cooperative purchasing vehicles; Texas represents emerging demand through exploratory procurement channels for direct manufacturer relationships.